左室補助人工心臓（LVAD）の世界市場-2023年～2030年

市場概要

左室補助人工心臓（LVAD）の世界市場は、2022年に14億米ドルに達し、2030年には23億米ドルに達するなど、有利な成長が見込まれています。世界の左室補助人工心臓（LVAD）市場は、予測期間（2023-2030年）にCAGR 7.2％を示すと予測されています。

左室補助人工心臓は、心臓の部屋から全身に血液を送り出すことによって、激しい症状や動作を伴う心不全患者に植え付けられる機械的循環支援戦略です。心不全の数の増加、新型の発売の増加、進歩、新興国市場の開拓の増加は、予測期間における世界の左室補助人工心臓（LVAD）市場の成長を後押しすると予想される要因の一つです。

市場力学

心不全患者の増加が左室補助人工心臓（LVAD）市場の成長を牽引

心不全の症例が増加していることが、予測期間における世界の左室補助人工心臓市場の成長を後押しすると予想されます。心不全は極めて典型的な疾患です。心不全は極めて典型的な疾患であり、複数の心臓疾患の治療において改善が見られるもの、心不全は世界的に関心が高まっています。例えば、アメリカ心不全学会によると、現在の評価では、20歳以上のアメリカ人のうち650万人近くが心不全を患っています。ある重要な調査評価によると、年間96万人以上の新生心不全患者がいます。心不全は相当数の個人に影響を与える重要な問題であるだけでなく、心不全は著名な殺人者ですらあります。心不全は米国における心臓疾患による死亡の約8.5％を直接占めています。また、ある評価では、心不全は心血管疾患による死亡の約36％に寄与しています。

研究活動の増加は、世界の左室補助人工心臓（LVAD）市場に成長機会をもたらすと予想されます

例えば、イスラエルに本拠を置くデバイスメーカーMagenta Medical社は、FDA認可を確実にするための最重要行動として、高リスク経皮的冠動脈インターベンション（HR-PCI）用の経皮的左室補助人工心臓（pLVAD）であるElevateの早期実現可能性調査を開始しています。

LVAD移植の高コストが予測期間中の世界の左室補助人工心臓（LVAD）市場を妨げると予測

LVAD移植の高コストは、予測期間における世界の左室補助人工心臓市場の成長を妨げると予測されています。例えば、NIHによると、LVAD移植の平均費用は175,420米ドルでした。しかし、LVADは心不全患者の生活の質を改善することが証明されているが、頻繁な再入院や費用のかかる経過観察のため、生涯コストは大幅に増加しています。

COVID-19影響分析

COVID-19のパンデミックと世界各国でのロックダウンにより、あらゆる業種の企業の財務の健全性が影響を受けています。そのため、COVID-19公衆衛生緊急事態の期間中、米国食品医薬品局（FDA）は、スポンサーと研究者を支援し、試験参加者の安全を確保し、適正臨床実施基準（GCP）を遵守し、試験の完全性に対するリスクを最小限に抑えるための一般的な考慮事項を含むガイドラインを発表しました。

ロシア・ウクライナ紛争の影響分析

ロシアとウクライナの紛争は、世界の左室補助人工心臓（LVAD）市場に中程度の影響を及ぼすと考えられています。ウクライナの診療所は、ロシア軍からの侵攻に耐え続けているもの、死者数の増加と限られた医療援助に追われています。あらゆる種類の医薬品が不足しています。繰り返しますが、原材料の輸出入の重要性は、予測期間における世界の左室補助人工心臓（LVAD）市場の成長に若干の影響を与えると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 製品認可の増加
    • 心不全患者の増加
  • 抑制要因
    • 高いコスト
  • 機会
    • 研究活動の増加
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 タイプ別

• 経皮的LVAD
• 埋め込み型LVAD
• その他

第8章 ポンプタイプ別

• 第一世代デバイス
• 第二世代デバイス
• 第三世代デバイス
• その他

第9章 用途別

• BTR療法
• BTT療法
• DT
• BTC療法
• その他

第10章 エンドユーザー別

• 病院
• 循環器センター
• その他

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • その他アジア太平洋地域
• 中東およびアフリカ
  • 主な地域別ダイナミクス

第12章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第13章 企業プロファイル

• CorWave.
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Apaxis Inc.
• Sunshine Heart.
• HeartWare International（Medtronic）
• Sun Medical Technology Research
• Abiomed
• Terumo Corporation
• Evaheart
• Jarvik Heart
• Thoratec（Abbott）

第14章 付録

Market Overview

The global left ventricular assist device (LVAD) market reached US$ 1.4 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 2.3 billion by 2030. The global left ventricular assist device (LVAD) market is expected to exhibit a CAGR of 7.2% during the forecast period (2023-2030).

Left Ventricular Assist Devices (VAD) are mechanical circulatory support strategies planted in heart failure individuals with intense manifestation and operation by pumping blood from the chambers of the heart to the entire body. The increase in the number of heart failures, rising type launches, advancements, and increasing market developments are among the factors expected to boost the global left ventricular assist device (LVAD) market growth in the forecast period.

Market Dynamics

Increasing Cases Of Heart Failure Drive The Growth Of The Left Ventricular Assist Device (LVAD) Market.

The increasing cases of heart failure are expected to boost the global left ventricle assist device market growth in the forecast period. Heart failure is extremely typical. Although improvement is created in the treatment of multiple states of heart conditions, heart failure is a growing concern globally. For instnace, according to the Heart Failure Society of America, the current assessments are that nearly 6.5 million Americans over the age of 20 suffer heart failure. One significant investigation assessment indicates that there are over 960,000 fresh heart failure patients yearly. Not only is heart failure a significant issue impacting a considerable number of individuals, but heart failure is even a prominent killer. Heart failure directly accounts for approximately 8.5% of all heart condition deaths in the United States. And, to some assessments, heart failure contributes to about 36% of all cardiovascular disease deaths.

The Increase in Research Activities is Expected To Present The Global Left Ventricular Assist Device (LVAD) Market With Growth Opportunities.

Increasing research initiatives are estimated to boost the global For instance, in the foremost action in ensuring FDA authorization, Israel-based device maker Magenta Medical is initiating a premature feasibility investigation with its Elevate percutaneous Left Ventricular Assist Device (pLVAD) for high-risk percutaneous coronary intervention (HR-PCI).

The High Cost of LVAD Implantation is Estimated To Hamper The Global Left Ventricular Assist Device (LVAD) Market During The Forecast Period.

The high cost of LVAD implantation is estimated to hamper the global left ventricular assist device market growth in the forecast period. For instance, according to the NIH, the mean cost of LVAD implantation was USD 175,420. However, LVADs proven heart failure patients improved quality of life but substantially increased lifetime costs because of frequent readmissions and costly follow-up care.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is thought to hold a moderate influence on the global left ventricular assist device (LVAD) market, as there is a low incidence of heart failure and a lack of primary market players in this region. Though continuing to countenance invasions from Russian armies, Ukrainian clinics are forced by growing numbers of deaths and limited medical aid. There are shortages across all types of medications. Again, the significance of the import and export of raw materials are expected to slightly impact the global Left Ventricular Assist Device (LVAD) market growth in the forecast period.

Segment Analysis

The global left ventricular assist device (LVAD) market is segmented based on type, pump type, application, end-user, and region.

The Implantable LVAD Type is Estimated to Dominate the Global Left Ventricular Assist Device (LVAD) Market.

Owing to the increase in the procedures of implantable LVAD, implantable LVAD is estimated to hold around 23.9% of the global market share by 2030. For instnace, in July 2022, a team from Emory's Heart and Vascular Center conducted its 500th continuous flow, durable left ventricular assist device (LVAD) implantation, additionally establishing Emory Healthcare's position as a national leader in the life-saving procedure.

Geographical Analysis

Europe is Estimated to Hold 27.1% of the Market Share Owing to the Key Player's Efforts in this Region.

Owing to the key player's efforts in the Europe region, the region is estimated to hold around 27.1% of the global market share. For instance, UK-based Calon Cardio-Technology Ltd. seeks to obtain the CE Mark for its MiniVAD in earlier 2024, by which period a US FDA Early Feasibility Study is expected to have been concluded. The corporation pursues to boost investments of almost USD 47 million (£34 million) to USD 60 million (£43 million) to finance its clinical investigations of the MiniVAD in the US and Europe from 2020 to 2023.

Competitive Landscape

The major global players in the Left Ventricular Assist Device (LVAD) market include: CorWave, Apaxis Inc., Sunshine Heart, HeartWare International (Medtronic), Sun Medical Technology Research, Abiomed, Terumo Corporation, Evaheart, Jarvik Heart, and Thoratec (Abbott), among others.

Why Purchase the Report?

• To visualize the global left ventricular assist device (LVAD) market segmentation based on type, pump type, application, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of left ventricular assist device (LVAD) market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Type mapping available in Excel consisting of key Types of all the major players.

The global left ventricular assist device (LVAD) market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Pump Type
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Product Approvals.
    • 4.1.1.2. Growing Incidences of Heart Failure.
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost.
  • 4.1.3. Opportunity
    • 4.1.3.1. Increasing Research Activities
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Transcutaneous LVAD *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Implantable LVAD
• 7.4. Others

8. By Pump Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pump Type
  • 8.1.2. Market Attractiveness Index, By Pump Type
• 8.2. First-Generation Devices*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Second-Generation Devices
• 8.4. Third-Generation Devices
• 8.5. Others

9. By Application

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.1.2. Market Attractiveness Index, By Application
• 9.2. Bridge-to-Recovery (BTR) Therapy *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Bridge-to-Transplant (BTT) Therapy
• 9.4. Destination Therapy
• 9.5. Bridge-to-Candidacy (BTC) Therapy
• 9.6. Others

10. By End User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 10.1.2. Market Attractiveness Index, By End User
• 10.2. Hospitals *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Cardiology Centers
• 10.4. Other

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pump Type
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. The U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pump Type
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. U.K.
    • 11.3.7.3. France
    • 11.3.7.4. Spain
    • 11.3.7.5. Italy
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pump Type
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pump Type
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan

Australia

• 11.5.7.4. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pump Type
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. CorWave.*
  • 13.1.1. Company Overview
  • 13.1.2. Type Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Apaxis Inc.
• 13.3. Sunshine Heart.
• 13.4. HeartWare International (Medtronic)
• 13.5. Sun Medical Technology Research
• 13.6. Abiomed
• 13.7. Terumo Corporation
• 13.8. Evaheart
• 13.9. Jarvik Heart
• 13.10. Thoratec (Abbott)

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us